Navigation Links
ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Date:2/11/2011

EXTON, Pa., Feb. 11, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference at 2:40 P.M. ET on Thursday, February 17, 2011.  The conference is being held at the Roosevelt Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Participate in the 29th Annual J.P. Morgan Healthcare Conference
2. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
3. ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010
4. ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human])
5. ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data
6. ViroPharma to Participate in Two May Healthcare Investor Conferences
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma to Present at Four Additional Healthcare Conferences
9. ViroPharma to Present at Several Upcoming Healthcare Conferences
10. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Electrospraying line of nanofiber and nanoparticle fabrication instruments from ... lab to fully automated pilot plants and equipment for industrial manufacturing. All ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Drug Administration (FDA) inspection at our Dilworth, MN site. The inspection took ... This inspection was conducted as part of a routine Bioresearch Monitoring Program (BIMO) ...
(Date:8/15/2017)... ... 15, 2017 , ... Kapstone Medical is proud to announce that ... technology companies and inventors develop and safeguard their latest innovations. The company has ... a portfolio of clients in the United States and around the world. , ...
(Date:8/15/2017)... Wisconsin (PRWEB) , ... August 15, 2017 , ... ... a new family of 6” modular downlights designed to stay tightly sealed and ... including areas where damp and wet location listings just aren't enough, such as: ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):